Literature DB >> 17364448

Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.

Matthias Hermann1, Frank Ruschitzka.   

Abstract

Since selective cyclooxygenase-2 inhibitors (coxibs) entered the market, there has been concern about the cardiovascular safety of coxibs. In addition, recent data suggest that classical non-steroidal anti-inflammatory drugs (NSAIDs) have a similar cardiovascular risk. Importantly, all of the clinical trials with NSAIDs and coxibs so far were not purpose-designed to specifically and prospectively address cardiovascular safety and were clearly underpowered to detect any meaningful differences. In this current uncertainty about safety of NSAIDs and coxibs, the definitive answer as to the net effect of coxibs and NSAIDs on cardiovascular events can only be provided by well designed adequately powered, long-term clinical trials, which is now under way.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17364448     DOI： 10.1080/07853890601073445

Source DB:  PubMed          Journal:  Ann Med        ISSN： 0785-3890            Impact factor:   4.709


  12 in total

1.  Inhibition of nuclear factor kappaB activation and cyclooxygenase-2 expression by aqueous extracts of Hispanic medicinal herbs.

Authors:  Robert A Orlando; Amanda M Gonzales; Lucy A Hunsaker; Carolina R Franco; Robert E Royer; David L Vander Jagt; Dorothy J Vander Jagt
Journal:  J Med Food       Date:  2010-08       Impact factor: 2.786

2.  Safety and efficacy of topical diclofenac sodium gel for knee osteoarthritis in elderly and younger patients: pooled data from three randomized, double-blind, parallel-group, placebo-controlled, multicentre trials.

Authors:  Herbert S B Baraf; F Michael Gloth; H Richard Barthel; Morris S Gold; Roy D Altman
Journal:  Drugs Aging       Date:  2011-01-01       Impact factor: 3.923

Review 3.  Focus on therapy of primary stabbing headache.

Authors:  Enrico Ferrante; Paolo Rossi; Cristina Tassorelli; Carlo Lisotto; Giuseppe Nappi
Journal:  J Headache Pain       Date:  2010-01-30       Impact factor: 7.277

Review 4.  A Comprehensive Review of Celecoxib Oral Solution for the Acute Treatment of Migraine.

Authors:  Nazir Noor; Courtney LaChute; Mathew Root; Jasmine Rogers; Madeleine Richard; Giustino Varrassi; Ivan Urits; Omar Viswanath; Nazih Khater; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-04-26

5.  Causes of death in patients with rheumatoid arthritis from 1971 to 1991 with special reference to autopsy.

Authors:  Riitta Koivuniemi; Leena Paimela; Marjatta Leirisalo-Repo
Journal:  Clin Rheumatol       Date:  2009-09-17       Impact factor: 2.980

6.  Causes of death in patients with rheumatoid arthritis autopsied during a 40-year period.

Authors:  R Koivuniemi; L Paimela; R Suomalainen; H Piirainen; M Karesoja; T Helve; M Leirisalo-Repo
Journal:  Rheumatol Int       Date:  2008-08-21       Impact factor: 2.631

7.  Fullerene nanomaterials inhibit phorbol myristate acetate-induced inflammation.

Authors:  Anthony Dellinger; Zhiguo Zhou; Robert Lenk; Darren MacFarland; Christopher L Kepley
Journal:  Exp Dermatol       Date:  2009-12       Impact factor: 3.960

8.  The use of etoricoxib to treat an idiopathic stabbing headache: a case report.

Authors:  Mortimer B O'Connor; Elizabeth Murphy; Mark J Phelan; Michael J Regan
Journal:  J Med Case Rep       Date:  2007-09-21

9.  Correlation of pain relief with physical function in hand osteoarthritis: randomized controlled trial post hoc analysis.

Authors:  H Richard Barthel; John H Peniston; Michael B Clark; Morris S Gold; Roy D Altman
Journal:  Arthritis Res Ther       Date:  2010-01-11       Impact factor: 5.156

10.  Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis--a population-based longitudinal follow-up study.

Authors:  Ya-Ping Huang; Yen-Ho Wang; Shin-Liang Pan
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.